BREAST CANCER RESEARCH FOUNDATION’S (BCRF) DRUG RESEARCH COLLABORATIVE
BCRF has received a 3-year, $15 million grant from Pfizer, along with access to all of Pfizer’s marketed and pipeline assets, to support its Drug Research Collaborative. The collaborative offers a new model for bridging the gap between academic investigators and the industry partners who can provide access to developmental oncology drugs.
The program will initially support 6 laboratory studies and 3 clinical trials that will collectively benefit nearly 400 patients with metastatic disease. The clinical studies will be conducted and managed by the Translational Breast Cancer Research Consortium (TBCRC).
Find out about BCRF’s Drug